Makoto Hiraide1, Taro Shiga2, Yuichi Minowa3, Yasuhiro Nakano3, Hidenori Yoshioka3, Kenichi Suzuki3, Chikao Yasuda4, Harumi Takahashi5, Toshihiro Hama3. 1. Department of Pharmacy, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Biopharmaceutics, Meiji Pharmaceutical University, Kiyose City, Tokyo, Japan. 2. Department of Onco-Cardiology/Cardiovascular Medicine, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: taro.shiga@jfcr.or.jp. 3. Department of Pharmacy, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 4. Department of Medical Safety Management, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 5. Department of Biopharmaceutics, Meiji Pharmaceutical University, Kiyose City, Tokyo, Japan.
Abstract
BACKGROUND: The reported incidence of venous thromboembolism (VTE) in cancer patients is 4-20%. The Khorana VTE risk score (KRS) and the Vienna VTE risk score (VRS) have been proposed as scoring models for evaluation of cancer-associated VTE. However, the risk factors of VTE in Japanese lung cancer patients have not been clarified. METHODS: This retrospective study included 682 hospitalized Japanese patients with newly diagnosed lung cancer who were examined for VTE on admission between January 2014 and December 2016. RESULTS: Seventy-one (10.4%) of the 682 patients were diagnosed with VTE. Multivariate logistic regression analysis showed that body mass index (BMI) ≥25 kg/m2 (OR, 2.02; 95% CI, 1.06-3.72), white blood cell (WBC) count >11 × 109/L (OR, 2.31; 95% CI, 1.11-4.61), pre-chemotherapy serum D-dimer concentration ≥1.44 μg/mL (OR, 2.73; 95% CI, 1.49-4.99), and non-small cell lung cancer (OR, 3.13; 95% CI, 1.32-9.23) were significantly associated with VTE in these patients. The cut-off values for BMI, WBC count, and D-dimer concentration determined using receiver operating characteristic curves were 25.4 kg/m2, 11.2 × 109/L, and 1.95 µg/mL, respectively. CONCLUSIONS: In this study, we were able to identify four independent risk factors for cancer-associated VTE in Japanese lung cancer patients for the first time. Moreover, we showed that a cut-off level of ≥25 kg/m2 for BMI was a risk factor for VTE in this cohort.
BACKGROUND: The reported incidence of venous thromboembolism (VTE) in cancerpatients is 4-20%. The Khorana VTE risk score (KRS) and the Vienna VTE risk score (VRS) have been proposed as scoring models for evaluation of cancer-associated VTE. However, the risk factors of VTE in Japanese lung cancerpatients have not been clarified. METHODS: This retrospective study included 682 hospitalized Japanese patients with newly diagnosed lung cancer who were examined for VTE on admission between January 2014 and December 2016. RESULTS: Seventy-one (10.4%) of the 682 patients were diagnosed with VTE. Multivariate logistic regression analysis showed that body mass index (BMI) ≥25 kg/m2 (OR, 2.02; 95% CI, 1.06-3.72), white blood cell (WBC) count >11 × 109/L (OR, 2.31; 95% CI, 1.11-4.61), pre-chemotherapy serum D-dimer concentration ≥1.44 μg/mL (OR, 2.73; 95% CI, 1.49-4.99), and non-small cell lung cancer (OR, 3.13; 95% CI, 1.32-9.23) were significantly associated with VTE in these patients. The cut-off values for BMI, WBC count, and D-dimer concentration determined using receiver operating characteristic curves were 25.4 kg/m2, 11.2 × 109/L, and 1.95 µg/mL, respectively. CONCLUSIONS: In this study, we were able to identify four independent risk factors for cancer-associated VTE in Japanese lung cancerpatients for the first time. Moreover, we showed that a cut-off level of ≥25 kg/m2 for BMI was a risk factor for VTE in this cohort.